Treatment of grass pollen allergy: Focus on a standardized grass allergen extract - Grazax®

Therapeutics and Clinical Risk Management

Volumn 4, Issue 6, 2008, Pages 1255-1260

  Calderón, Moiśes ^a   Brandt, Tove ^b  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b ALK ABELLÓ   (Denmark)

Author keywords

Grass pollen allergy; Immunotherapy; Rhinoconjunctivitis; Sublingual immonotherapy; Tablet

Indexed keywords

ALUTARD; ALUTARD SQ; GRASS POLLEN VACCINE; IMMUNOGLOBULIN E; IMMUNOMODULATING AGENT; PLACEBO; UNCLASSIFIED DRUG;

ASTHMA; CLINICAL TRIAL; CONJUNCTIVITIS; COUGHING; CROSS REACTION; DISEASE CONTROL; DOSE RESPONSE; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; EAR PRURITUS; FATIGUE; GRASS POLLEN; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INJECTION SITE REACTION; MOUTH EDEMA; NOSE CONGESTION; OCULAR PRURITUS; ORAL PARESTHESIA; ORAL PRURITUS; PATIENT COMPLIANCE; PHARYNGITIS; PHLEUM PRATENSE; PRURITUS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REGULATORY T LYMPHOCYTE; REVIEW; RHINITIS; RHINOCONJUNCTIVITIS; RHINORRHEA; SIDE EFFECT; SNEEZING; TH2 CELL; THROAT IRRITATION; THROAT TIGHTNESS;

EID: 61549138170     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/tcrm.s3544     Document Type: Review

References (25)

1. Andersson K, Lidholm J. 2003. Characteristics and immunobiology of grass pollen allergens. Int Arch Allergy Immunol, 130:87-107.
2. Bagnasco M, Altrinetti V, Pesce G, et al. 2005. Pharmacokinetics of Der p 2 allergen and derived monomeric allergoid in allergic volunteers. Int Arch Allergy Immunol, 138:197-202.
3. Bagnasco M, Morbelli S, Altrinetti V, et al. 2003. Allergen biodistribution in humans. Chem Immunol Allergy, 82:33-43.
4. Bauchau V, Durham SR. 2004. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J, 24:758-64.
5. Bousquet J, Lockey RF, Malling HJ. 1998. WHO Position Paper. Allergen immunotherapy: Therapeutic vaccines for allergic diseases. Allergy, 53:1-42.
6. Calderon M, Essendrop M. 2006. Specific immunotherapy with high dose SQ standardised grass allergen tablets was safe and well tolerated. J Investig Allergol Clin Immunol, 16:338-44.
7. Calderon MA, Birk AO, Andersen JS, et al. SR. 2007. Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy. Allergy, 62:958-61.
8. Canonica GW, Baena-Cagnani CE, Bousquet J, et al. 2007. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for Respiratory allergy. A statement of the World Allergy Organization (WAO) taskforce. Allergy, 62:317-24.
9. Dahl R, Andersen PS, Chivato T, et al. 2004. National prevalence of respiratory allergic disorders. Respir Med, 98:398-403.
10. Dahl R, Kapp A, Colombo G, et al. 2008. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol, 121:512-8.
11. Dahl R, Kapp A, Golombo G, et al. 2006. Efficacy and safety of sublingual immunotherapy with grass allergen tablet for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol, 118:434-40.
12. Dahl R, Stender A, Rak S. 2006. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhino-conjunctivitis. Allergy, 61:185-90.
13. Durham SR, Riis B. 2007. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage. Allergy, 62:954-7.
14. Durham SR, Yang WH, Pedersen MR, et al. 2006. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol, 117:802-09.
15. Frew AJ, Powell RJ, Corrigan CJ, et al. 2006. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol, 117:319-25.
16. Ibanez MD, Kaiser F, Knecht R, et al. 2007. Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children. Pediatr Allergy Immunol, 18:516-22.
17. Juniper EF, Guyatt GH. 1991. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy, 21:77-83.
18. Kleine-Tebbe J, Ribel M, Herold DA. 2006. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy, 61:181-4.
19. Linneberg A, Nielsen NH, Madsen F, et al. 2000. Increasing prevalence of specific IgE to aeroallergens in an adult population: two cross-sectional surveys 8 years apart: the Copenhagen Allergy Study. J Allergy Clin Immunol, 106:247-52.
20. Malling H-J, Lund L, Ipsen H, et al. 2006. Safety and immunological changes during specific sublingual immunotherapy with SQ standardized grass allergen tablets. Journal Investig Allergol Clin Immunol, 16:162-8.
21. Moingeon P, Batard T, Fadel R, et al. 2006. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy, 61:151-65.
22. Rak S, Yang WH, Pedersen MR, et al. 2007. Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: a double-blind, randormsed study. Qual Life Res, 16:191-201.
23. Senel S, Kremer M, Nagy K, et al. 2001. Delivery of bioactive peptides and proteins across oral (buccal) mucosa. Curr Pharm Biotechnol, 2:175-86.
24. Weber RW 2005. Cross-reactivity of pollen allergens: recommendations for immunotherapy vaccines. Curr Opin Allergy Clin Immunol, 5:563-9.
25. White P, Smith H, Baker N, et al. 1998. Symptom control in patients with hay fever in UK general practice: how well are we doing and is there a need for allergen immunotherapy? Clin Exp Allergy, 28:266-70.